HDAC inhibitor-based therapies: can we interpret the code?

HDAC inhibitor-based therapies: can we interpret the code?

Abnormal epigenetic control is a common early event in tumour progression, and aberrant acetylation in particular has been implicated in tumourigenesis. One of the most promising approaches towards drugs that modulate epigenetic processes has been seen in the development of inhibitors of histone dea...

Disgrifiad llawn

Manylion Llyfryddiaeth
Prif Awduron:	New, M, Olzscha, H, La Thangue, N
Fformat:	Journal article
Iaith:	English
Cyhoeddwyd:	2012

Eitemau Tebyg

The TLR adaptor protein MyD88 mediates cell sensitivity to HDAC inhibitors through a cytokine-dependent mechanism
gan: Sheikh, S, et al.
Cyhoeddwyd: (2016)

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors.
gan: New, M, et al.
Cyhoeddwyd: (2013)

A regulatory circuit that involves HR23B and HDAC6 governs the biological response to HDAC inhibitors
gan: New, M, et al.
Cyhoeddwyd: (2013)

HDAC inhibitor-based therapies and haematological malignancy.
gan: Stimson, L, et al.
Cyhoeddwyd: (2009)

TLR adaptor protein MYD88 mediates sensitivity to HDAC inhibitors via a cytokine-dependent mechanism
gan: New, M, et al.
Cyhoeddwyd: (2016)

Biomarkers for predicting clinical responses to HDAC inhibitors.
gan: Stimson, L, et al.
Cyhoeddwyd: (2009)

HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
gan: Khan, O, et al.
Cyhoeddwyd: (2012)

HR23B is a biomarker for tumor sensitivity to HDAC inhibitor-based therapy.
gan: Khan, O, et al.
Cyhoeddwyd: (2010)

Impact of HDAC Inhibitors on Protein Quality Control Systems: Consequences for Precision Medicine in Malignant Disease
gan: Linda Anna Michelle Kulka, et al.
Cyhoeddwyd: (2020-06-01)

Role of HR23B, HDAC6 and Myd88 and their interplay in response to HDAC inhibitor treatment
gan: New, M
Cyhoeddwyd: (2014)

The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
gan: Liu, G, et al.
Cyhoeddwyd: (2023)

Immune modulation underpins the anti‐cancer activity of HDAC inhibitors
gan: Wiktoria Blaszczak, et al.
Cyhoeddwyd: (2021-12-01)

The HDAC inhibitor zabadinostat is a systemic regulator of adaptive immunity
gan: Geng Liu, et al.
Cyhoeddwyd: (2023-01-01)

Genome-wide loss-of-function screen reveals an important role for the proteasome in HDAC inhibitor-induced apoptosis.
gan: Fotheringham, S, et al.
Cyhoeddwyd: (2009)

Select HDAC Inhibitors Enhance Osteolysis and Bone Metastasis Outgrowth but Can Be Mitigated With Bisphosphonate Therapy
gan: Miranda E Clements, et al.
Cyhoeddwyd: (2023-03-01)

Drug Insight: histone deacetylase inhibitor-based therapies for cutaneous T-cell lymphomas.
gan: Khan, O, et al.
Cyhoeddwyd: (2008)

HDAC Inhibitors for the Therapy of Triple Negative Breast Cancer
gan: Cristina Maccallini, et al.
Cyhoeddwyd: (2022-05-01)

CBP/p300 bromodomains regulate amyloid-like protein aggregation upon aberrant lysine acetylation
gan: Olzscha, H, et al.
Cyhoeddwyd: (2016)

Bromodomains control amyloid-like aggregation of aberrantly acetylated proteins
gan: Olzscha, H, et al.
Cyhoeddwyd: (2018)

Metabolism, HDACs, and HDAC Inhibitors: A Systems Biology Perspective
gan: Jacob King, et al.
Cyhoeddwyd: (2021-11-01)

Can We Interpret Implicitness?
gan: Dilem Dinc, et al.
Cyhoeddwyd: (2023-12-01)

Involvement of HDAC1 and HDAC3 in the Pathology of Polyglutamine Disorders: Therapeutic Implications for Selective HDAC1/HDAC3 Inhibitors
gan: Elizabeth A. Thomas
Cyhoeddwyd: (2014-05-01)

Continuous Activity Assay for HDAC11 Enabling Reevaluation of HDAC Inhibitors
gan: Zsófia Kutil, et al.
Cyhoeddwyd: (2019-11-01)

Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies
gan: Wanli Zhang, et al.
Cyhoeddwyd: (2025-02-01)

SERPINA3-ANKRD11-HDAC3 pathway induced aromatase inhibitor resistance in breast cancer can be reversed by HDAC3 inhibition
gan: Jing Zhou, et al.
Cyhoeddwyd: (2023-07-01)

Current HDAC Inhibitors in Clinical Trials
gan: Elisabetta Di Bello, et al.
Cyhoeddwyd: (2022-05-01)

The Effect of Quisinostat as the HDAC Inhibitor on Migration
gan: Marjan Hajimoradi Javarsiani, et al.
Cyhoeddwyd: (2021-08-01)

The Effect of Quisinostat as the HDAC Inhibitor on Migration
gan: Marjan Hajimoradi Javarsiani, et al.
Cyhoeddwyd: (2021-08-01)

Phosphorus containing analogues of SAHA as inhibitors of HDACs
gan: Michael D. Pun, et al.
Cyhoeddwyd: (2022-12-01)

Overcoming resistance to anabolic SARM therapy in experimental cancer cachexia with an HDAC inhibitor
gan: Sophia G Liva, et al.
Cyhoeddwyd: (2020-01-01)

HDAC1/2 inhibitor therapy improves multiple organ systems in aged mice
gan: Alessandra Tammaro, et al.
Cyhoeddwyd: (2024-01-01)

Synergistic Enhancement of Cancer Therapy Using HDAC Inhibitors: Opportunity for Clinical Trials
gan: Lourdes Hontecillas-Prieto, et al.
Cyhoeddwyd: (2020-09-01)

Hydroxyl Ketone-Based Histone Deacetylase Inhibitors To Gain Insight into Class I HDAC Selectivity versus That of HDAC6
gan: Mohamed D. M. Traoré, et al.
Cyhoeddwyd: (2017-04-01)

Effects of structurally distinct human HDAC6 and HDAC6/HDAC8 inhibitors against S. mansoni larval and adult worm stages.
gan: Roberto Gimmelli, et al.
Cyhoeddwyd: (2024-02-01)

HDAC Inhibitors: Innovative Strategies for Their Design and Applications
gan: Mateusz Daśko, et al.
Cyhoeddwyd: (2022-01-01)

Histone Deacetylase (HDAC) Inhibitors for the Treatment of Schistosomiasis
gan: Ehab Ghazy, et al.
Cyhoeddwyd: (2022-01-01)

The Lethality of [Pazopanib + HDAC Inhibitors] Is Enhanced by Neratinib
gan: Laurence Booth, et al.
Cyhoeddwyd: (2019-07-01)

Diversity within the pRb pathway: is there a code of conduct?
gan: Munro, S, et al.
Cyhoeddwyd: (2012)

Optimization of Resveratrol Used as a Scaffold to Design Histone Deacetylase (HDAC-1 and HDAC-2) Inhibitors
gan: Beatriz Silva Urias, et al.
Cyhoeddwyd: (2022-10-01)

Analysis of the effect of HDAC inhibitors on the formation of the HIV reservoir
gan: Lijun Ling, et al.
Cyhoeddwyd: (2024-09-01)